Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.

Synthetic nanoparticles containing rapamycin — a common immunosuppressant drug — when co-administered with any free antigen can induce immune tolerance, offering a way to rescue novel drugs that have failed in the clinic due to antidrug antibodies.